Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

BACKGROUND: Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti‐angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Qi, Ling, Wang, Xi, Xu, Jianping, Liu, Yun, Mu, Lan, Wang, Xingyuan, Bai, Lidan, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7743020/
https://www.ncbi.nlm.nih.gov/pubmed/33314747
http://dx.doi.org/10.1002/cac2.12119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7743020/
https://www.ncbi.nlm.nih.gov/pubmed/33314747
http://dx.doi.org/10.1002/cac2.12119

Ejemplares similares